Abstract
Aim:
To design and synthesize a series of novel amino acid-binding 1,5-diarylpyrazole derivatives, which are intended to act as prodrugs with better aqueous solubility than celecoxib, and which will exert potent anti-inflammatory activities after being converted to their parent compounds in vivo.
Methods:
To introduce an amino acid, celecoxib analogs containing amino or methylamino group were synthesized first through multi-step chemical reactions. All the synthesized compounds were screened in an intact cell-based assay in vitro and in carrageenan-induced mouse paw edema in vivo. Some active compounds were selected for further evaluation in a carrageenan-induced rat paw edema model. The preliminary pharmacokinetics experiments were conducted using high performance liquid chromatography/mass spectrometry (HPLC/MS).
Results:
Celecoxib, 6 of the 1,5-diarylpyrazole class of celecoxib analogs, and their amino acid derivatives (hydrochloride salts) were synthesized. In vitro screening, the hydrochloride salts showed decreased inhibitory effects on cyclooxygenase (COX)-1 and COX-2 compared with their parent compounds, but some exhibited potent anti-inflammatory activity in vivo. Compound 4a was selected for further evaluation, and its anti-inflammatory effect was equivalent to that of celecoxib after oral administration in the carrageenan-induced rat paw edema model. At three doses (25 mg/kg, 50 mg/kg, and 100 mg/kg) the percentage inhibition on edema was 20.7%, 52.6%, and 62.6% (for compound 4a) and 27.8%, 38.4%, and 40.1% (for celecoxib), respectively. Preliminary pharmacokinetic evaluations support the hypothesis that compound 4a was actually converted to its parent compound, compound 4.
Conclusion:
The compound bound with amino acid acts like prodrug, which can exert anti-inflammatory effect similar to celecoxib after being converted to its parent compound. This finding will be of great benefit in carrying out structural modifications of prodrug-like selective COX-2 inhibitors.
Similar content being viewed by others
Article PDF
References
Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL . Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692–6.
Vane JR, Bakhle YS, Botting RM . Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97–120.
Smith WL, Garavito RM, DeWitt DL . Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; 271: 33157–60.
Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228–32.
Uddin MJ, Rao PN, McDonald R, Knaus EE . Design and synthesis of (E)-1,1,2-triarylethenes: novel inhibitors of the cyclooxygenase-2 (COX-2) isozyme. Bioorg Med Chem Lett 2005; 15: 439–42.
Ranatunge RR, Augustyniak M, Bandarage UK, Earl RA, Ellis JL, Garvey DS, et al. Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles. J Med Chem 2004; 47: 2180–93.
Hinz B, Brune K . Cyclooxygenase-2: 10 years later. J Pharmacol Exp Ther 2002; 300: 367–75.
Dannhardt G, Kiefer W . Cyclooxygenase inhibitors: current status and future prospects. Eur J Med Chem 2001; 36: 109–26.
Chen XH, Bai JY, Shen F, Bai AP, Guo ZR, Cheng GF . Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Acta Pharmacol Sin 2004; 25: 927–31.
Singh SK, Vobbalareddy S, Shivaramakrishna S, Krishnamraju A, Rajjak SA, Casturi SR, et al. Methanesulfonamide group at position-4 of the C-5-phenyl ring of 1,5-diarylpyrazole affords a potent class of cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med Chem Lett 2004; 14: 1683–8.
Ranatunge RR, Garvey DS, Janero DR, Letts LG, Martino AM, Murty MG, et al. Synthesis and selective cyclooxygenase-2 (COX-2) inhibitory activity of a series of novel bicyclic pyrazoles. Bioorg Med Chem 2004; 12: 1357–66.
Uddin MJ, Rao PN, Knaus EE . Design and synthesis of novel celecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of the sulfonamide pharmacophore by a sulfonylazide bioisostere. Bioorg Med Chem 2003; 11: 5273–80.
Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem 1997; 40: 1347–65.
Chawla G, Gupta P, Thilagavathi R, Chakraborti AK, Bansal AK . Characterization of solid-state forms of celecoxib. Eur J Pharm Sci 2003; 20: 305–17.
Pal M, Madan M, Padakanti S, Pattabiraman VR, Kalleda S, Vanguri A, et al. Synthesis and cyclooxygenase-2 inhibiting property of 1,5-diarylpyrazoles with substituted benzenesulfonamide moiety as pharmacophore: preparation of sodium salt for injectable formulation. J Med Chem 2003; 46: 3975–84.
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520–8.
Couzin J . Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science 2004; 306: 384–5.
Davies NM, Jamali F . COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharm Pharm Sci 2004; 7: 332–6.
Velazquez C, Rao PN, McDonald R, Knaus EE . Synthesis and biological evaluation of 3,4-diphenyl-1,2,5-oxadiazole-2-oxides and 3,4-diphenyl-1,2,5-oxadiazoles as potential hybrid COX-2 inhibitor/nitric oxide donor agents. Bioorg Med Chem 2005; 13: 2749–57.
Chen QH, Rao PN, Knaus EE . Design, synthesis, and biological evaluation of N-acetyl-2-carboxybenzenesulfonamides: a novel class of cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med Chem 2005; 13: 2459–68.
Dogne JM, Supuran CT, Pratico D . Adverse cardiovascular effects of the coxibs. J Med Chem 2005; 7: 2251–7.
Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan B, et al. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther 2001; 297: 638–45.
Benington F, Morin RD, Leiand CC . Mescaline analogs, VIII. Substituted 5-methoxy- and 5,6,7-trimethoxyindoles. J Org Chem 1958; 23: 19–23.
Walker HG, Hauser CR . Synthesis of methyl ketones from diethyl acylmalonates. J Am Chem Soc 1946; 68: 1386–8.
Zhang WY, Yang XN, Jin DZ, Zhu XZ, Chen XH, Bai JY, et al. Expression and enzyme activity determination of human cyclooxygenase-1 and -2 in a baculovirus-insect cell system. Acta Pharmacol Sin 2004; 25: 1000–6.
Winter CA, Risley EA, Nuss GW . Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med 1962; 111: 544–7.
Werner U, Werner D, Pahl A, Mundkowski R, Gillich M, Brune K . Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. Biomed Chromatogr 2002; 16: 56–60.
Mamidi RN, Mullangi R, Kota J, Bhamidipati R, Khan AA, Katneni K, et al. Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats. Biopharm Drug Dispos 2002; 23: 273–82.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Li, Mh., Yin, Ll., Cai, Mj. et al. Design, synthesis, and anti-inflammatory evaluation of a series of novel amino acid-binding 1,5-diarylpyrazole derivatives. Acta Pharmacol Sin 26, 865–872 (2005). https://doi.org/10.1111/j.1745-7254.2005.00151.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2005.00151.x